| Authors: |
Gorovits B; Regeneron Pharmaceuticals, Inc, Tarrytown, USA. boris.gorovits@regeneron.com., Azadeh M; Progeria Research Foundation, Inc., Cambridge, Massachusetts, USA., Fiscella M; REGENXBIO Inc, Rockville, USA., Harrison T; Precision for Medicine Inc., Frederick, Maryland, USA., Hofer M; Jefferson Institute for Bioprocessing, Lower Gwynedd, USA., Janetzki S; ZellNet Consulting, Inc, Fort Lee, New Jersey, USA., Jawa V; EpiVax, Inc, Providence, Rhode Island, USA., Long B; 4D Molecular Therapeutics, Emeryville, USA., Lu Y; Sangamo Therapeutics, Inc, Richmond, USA., Mahnke YD; FlowKnowHow LLC, New York, USA., Maia M; South San Francisco, CA, USA., Majumdar R; LabCorp Holdings, Inc, Burlington, USA., Miller M; Miller Bioanalytical Consulting LLC, Carlsbad, USA., Milton M; Lake Boon Pharmaceutical Consulting, LLC, Hudson, USA., Nelson R; BioAgilytix Labs, LLC, Durham, USA., Partridge MA; Regeneron Pharmaceuticals, Inc, Tarrytown, USA., Shaik S; Takeda Pharmaceutical Company Limited, Cambridge, USA., Snoeck V; UCB, B-1420, Braine-l'Alleud, Belgium., Vettermann C; 4D Molecular Therapeutics, Emeryville, USA., Wu B; Johnson & Johnson Innovative Medicine, Titusville, USA., Zhao A; Regeneron Pharmaceuticals, Inc, Tarrytown, USA. |
